Letters NICE’s end of life decision making scheme

Analysis of the impact of extending end of life treatments should be treated with caution

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3249 (Published 24 May 2013) Cite this as: BMJ 2013;346:f3249
  1. Paul Catchpole, director1
  1. 1Association of the British Pharmaceutical Industry, London SW1E 6QT, UK
  1. pressoffice{at}abpi.org.uk

Collins and Latimer recently estimated the effect on the NHS of the supplementary advice on life extending end of life treatments introduced by the National Institute for Health and Care (formerly Clinical) Excellence (NICE) in 2009.1 2 Their study shows how NICE’s cost effectiveness threshold should work in …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe